Sequenom's Shares Rise on Genotyping Test Launch | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom were up around 7 percent at $4.36 in mid-afternoon trade on the Nasdaq, after the firm announced the launch of its SensiGene Fetal RHD Genotyping test.

The test will be offered through Sequenom's CAP-credited and CLIA-certified lab, the Sequenom Center for Molecular Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.